Market overview
The global vaginitis screening assays market is worth USD 821 mn in 2026 and is forecast to reach USD 1.7 bn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Molecular multiplex panels is the largest by technology segment.
| Scope | Laboratory and point-of-care tests that detect the causes of vaginal infection: bacterial vaginosis, Candida and Trichomonas, as multiplex molecular panels, rapid tests and conventional assays. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 760 mn |
| Value 2026 | USD 821 mn |
| Value 2036 | USD 1.7 bn |
| CAGR 2026-2036 | 7.5% |
| Volume 2026 | 30.2 million tests |
| Volume 2036 | 62.3 million tests |
| Average price 2026 | USD 27.1 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Vaginitis Screening Assays market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 821 mn |
| 2027 | USD 882 mn |
| 2028 | USD 949 mn |
| 2029 | USD 1.0 bn |
| 2030 | USD 1.1 bn |
| 2031 | USD 1.2 bn |
| 2032 | USD 1.3 bn |
| 2033 | USD 1.4 bn |
| 2034 | USD 1.5 bn |
| 2035 | USD 1.6 bn |
| 2036 | USD 1.7 bn |
Vaginitis Screening Assays market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Molecular multiplex panels | 52.0% | 62.7% | USD 427 mn | 9.5% |
| Point-of-care rapid tests | 24.0% | 23.0% | USD 197 mn | 7.0% |
| Conventional culture and microscopy | 24.0% | 14.3% | USD 197 mn | 2.1% |
By pathogen
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Bacterial vaginosis | 36.0% | 35.3% | USD 295 mn | 7.3% |
| Candida | 30.0% | 28.1% | USD 246 mn | 6.8% |
| Trichomonas | 22.0% | 22.6% | USD 181 mn | 7.8% |
| Mixed panels | 12.0% | 14.1% | USD 98 mn | 9.3% |
By sample
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Vaginal swab | 62.0% | 60.0% | USD 509 mn | 7.2% |
| Urine | 20.0% | 20.0% | USD 164 mn | 7.5% |
| Self-collected | 18.0% | 20.0% | USD 148 mn | 8.6% |
By setting
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospital labs | 32.0% | 28.0% | USD 263 mn | 6.1% |
| Clinic labs | 28.0% | 28.0% | USD 230 mn | 7.5% |
| Reference labs | 26.0% | 26.0% | USD 213 mn | 7.5% |
| At-home kits | 14.0% | 18.0% | USD 115 mn | 10.2% |
By platform
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| PCR | 34.0% | 38.0% | USD 279 mn | 8.7% |
| Immunoassay | 26.0% | 24.0% | USD 213 mn | 6.6% |
| Microscopy and culture | 40.0% | 38.0% | USD 328 mn | 7.0% |
Top 25 countries for vaginitis screening assays by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 91.0% of 2026 revenue and the 25 countries below together hold 97.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 427 mn | 52.0% | USD 861 mn | 7.3% |
| 2 | China | USD 66 mn | 8.0% | USD 183 mn | 10.8% |
| 3 | Germany | USD 49 mn | 6.0% | USD 95 mn | 6.8% |
| 4 | France | USD 41 mn | 5.0% | USD 80 mn | 6.8% |
| 5 | United Kingdom | USD 37 mn | 4.5% | USD 71 mn | 6.8% |
| 6 | Japan | USD 33 mn | 4.0% | USD 61 mn | 6.4% |
| 7 | Italy | USD 25 mn | 3.0% | USD 47 mn | 6.8% |
| 8 | Brazil | USD 25 mn | 3.0% | USD 58 mn | 8.8% |
| 9 | Spain | USD 25 mn | 3.0% | USD 47 mn | 6.8% |
| 10 | Canada | USD 21 mn | 2.5% | USD 41 mn | 7.1% |
| 11 | Australia | USD 11 mn | 1.4% | USD 21 mn | 6.1% |
| 12 | Mexico | USD 6.8 mn | 0.8% | USD 18 mn | 9.9% |
| 13 | South Korea | USD 5.0 mn | 0.6% | USD 9.1 mn | 6.2% |
| 14 | Netherlands | USD 4.1 mn | 0.5% | USD 7.4 mn | 6.1% |
| 15 | Turkey | USD 3.5 mn | 0.4% | USD 8.8 mn | 9.8% |
| 16 | Switzerland | USD 3.0 mn | 0.4% | USD 5.4 mn | 6.0% |
| 17 | Belgium | USD 2.7 mn | 0.3% | USD 4.9 mn | 6.1% |
| 18 | Poland | USD 2.4 mn | 0.3% | USD 6.3 mn | 10.2% |
| 19 | Russia | USD 2.2 mn | 0.3% | USD 4.1 mn | 6.2% |
| 20 | Sweden | USD 2.0 mn | 0.2% | USD 3.7 mn | 6.1% |
| 21 | Argentina | USD 1.9 mn | 0.2% | USD 4.9 mn | 10.0% |
| 22 | Taiwan | USD 1.8 mn | 0.2% | USD 3.2 mn | 5.9% |
| 23 | Austria | USD 1.6 mn | 0.2% | USD 3.0 mn | 6.4% |
| 24 | Thailand | USD 1.6 mn | 0.2% | USD 4.1 mn | 10.0% |
| 25 | Saudi Arabia | USD 1.5 mn | 0.2% | USD 3.9 mn | 10.2% |
| Rest of world | USD 22 mn | 2.7% | USD 42 mn | 6.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Roche Diagnostics
- Hologic
- BD
- Abbott
Group 2: Regional and specialist players
- Cepheid
- Seegene
- Sekisui Diagnostics
- bioMerieux
- DiaSorin
- Qiagen
- Vircell
- Savyon Diagnostics
- Trinity Biotech
Group 3: Emerging and niche players
- Biosynex
- Visby Medical
- Evvy
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the vaginitis screening assays market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.5% is calculated from the resulting values.
The market is divided by technology, by pathogen, by sample, by setting, by platform. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the vaginitis screening assays market?
The global vaginitis screening assays market is estimated at USD 760 mn in 2025 and USD 821 mn in 2026.
How fast will the vaginitis screening assays market grow?
It is forecast to reach USD 1.7 bn by 2036, a compound annual growth rate of 7.5% from 2026, an increase of USD 871 mn.
Which country is the largest market for vaginitis screening assays?
United States is the largest market by revenue at USD 427 mn in 2026, 52.0% of the global total. The three largest countries together hold 66.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 10.8% a year from 2026 to 2036.
Which vaginitis screening assays segment is largest?
In the by technology split, Molecular multiplex panels is the largest segment with 52.0% of 2026 revenue.
Who are the leading vaginitis screening assays companies?
Global leaders include Roche Diagnostics, Hologic, BD, Abbott.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Endoscopic Closure SystemsUSD 817 mn · 7.0% CAGR
- Behavioral Health Care CoordinationUSD 806 mn · 11.0% CAGR
- AI based Triage ToolsUSD 802 mn · 16.0% CAGR
- Perimenopause Nutrition ProductsUSD 852 mn · 6.0% CAGR
- Absorbable PGLA Surgical SuturesUSD 853 mn · 4.0% CAGR
- Precision Transplant MedicineUSD 770 mn · 9.5% CAGR
- AI-Powered Behavioral TherapyUSD 768 mn · 17.0% CAGR
- AI-powered Spinal SurgeryUSD 881 mn · 12.0% CAGR
← Vaccines Vaporized Hydrogen Peroxide Sterilization System →